Cargando…

FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA)

Disclosure: D. van Rooyen: None. R. Scheske: None. A.M. Lerario: None. W.E. Rainey: None. R.J. Auchus: None. G.D. Hammer: None. T. Else: None. Background: Adrenal tumors are very common, with the vast majority being benign adrenocortical adenomas (ACA). Adrenocortical carcinomas (ACC) represent only...

Descripción completa

Detalles Bibliográficos
Autores principales: van Rooyen, Desmaré, Scheske, Rachel, Lerario, Antonio Marcondes, Rainey, William E, Auchus, Richard Joseph, Hammer, Gary D, Else, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554608/
http://dx.doi.org/10.1210/jendso/bvad114.187
_version_ 1785116452811964416
author van Rooyen, Desmaré
Scheske, Rachel
Lerario, Antonio Marcondes
Rainey, William E
Auchus, Richard Joseph
Hammer, Gary D
Else, Tobias
author_facet van Rooyen, Desmaré
Scheske, Rachel
Lerario, Antonio Marcondes
Rainey, William E
Auchus, Richard Joseph
Hammer, Gary D
Else, Tobias
author_sort van Rooyen, Desmaré
collection PubMed
description Disclosure: D. van Rooyen: None. R. Scheske: None. A.M. Lerario: None. W.E. Rainey: None. R.J. Auchus: None. G.D. Hammer: None. T. Else: None. Background: Adrenal tumors are very common, with the vast majority being benign adrenocortical adenomas (ACA). Adrenocortical carcinomas (ACC) represent only a very small proportion of adrenal tumors. Distinction between the common ACA and rare ACC relies on invasive and costly protocols which are often inconclusive. Research into the use of steroid biomarkers as a non-invasive alternative diagnostic tool has been the focus of various steroid metabolomics studies. In this study, we aimed to identify serum steroid biomarkers to distinguish ACA from ACC. Methods: This study population was comprised of 103 patient samples, including 45 (31 female) and 58 (40 female) respective samples from ACA (age 32-90) and ACC (age 16-77) patients presenting with disease at the time of sampling. No ACC patients studied had been treated with mitotane. Serum steroid levels (4 sulfates and 25 Δ4 steroids) were measured using liquid-chromatography tandem mass spectrometry (LCMS/MS) with comparisons made between steroid profiles in ACA vs ACC and between males and females within each group (ACA and ACC). Data were analyzed to obtain the geometric means with 95% CIs, and statistical significance was determined using a two-tailed Mann-Whitney test. Results: ACC patients were characterized by significantly elevated levels of pregnenolone-sulfate, 17hydroxypregnenolone-sulfate, 11-deoxycorticosterone, 17hydroxyprogesterone, and androstenedione when compared to ACA patients. In addition, steroid levels differed between male and female samples, with dehydroepiandrosterone-sulfate (p<0.01), androstenediol-3-sulfate (p<0.05), 11deoxycortisol (p<0.0001), cortisol (p<0.05) and testosterone (p<0.01) significantly increased in female ACC patients when compared to male counterparts. Conclusion: Significant differences in plasma steroids were observed in ACC vs ACA patients, with more steroids altered in female patients. Serum steroid profiles, particularly steroid sulfates, might serve as an adjunct, easy to obtain diagnostic tool to differentiate ACA and ACC. Presentation: Friday, June 16, 2023
format Online
Article
Text
id pubmed-10554608
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105546082023-10-06 FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA) van Rooyen, Desmaré Scheske, Rachel Lerario, Antonio Marcondes Rainey, William E Auchus, Richard Joseph Hammer, Gary D Else, Tobias J Endocr Soc Adrenal (Excluding Mineralocorticoids) Disclosure: D. van Rooyen: None. R. Scheske: None. A.M. Lerario: None. W.E. Rainey: None. R.J. Auchus: None. G.D. Hammer: None. T. Else: None. Background: Adrenal tumors are very common, with the vast majority being benign adrenocortical adenomas (ACA). Adrenocortical carcinomas (ACC) represent only a very small proportion of adrenal tumors. Distinction between the common ACA and rare ACC relies on invasive and costly protocols which are often inconclusive. Research into the use of steroid biomarkers as a non-invasive alternative diagnostic tool has been the focus of various steroid metabolomics studies. In this study, we aimed to identify serum steroid biomarkers to distinguish ACA from ACC. Methods: This study population was comprised of 103 patient samples, including 45 (31 female) and 58 (40 female) respective samples from ACA (age 32-90) and ACC (age 16-77) patients presenting with disease at the time of sampling. No ACC patients studied had been treated with mitotane. Serum steroid levels (4 sulfates and 25 Δ4 steroids) were measured using liquid-chromatography tandem mass spectrometry (LCMS/MS) with comparisons made between steroid profiles in ACA vs ACC and between males and females within each group (ACA and ACC). Data were analyzed to obtain the geometric means with 95% CIs, and statistical significance was determined using a two-tailed Mann-Whitney test. Results: ACC patients were characterized by significantly elevated levels of pregnenolone-sulfate, 17hydroxypregnenolone-sulfate, 11-deoxycorticosterone, 17hydroxyprogesterone, and androstenedione when compared to ACA patients. In addition, steroid levels differed between male and female samples, with dehydroepiandrosterone-sulfate (p<0.01), androstenediol-3-sulfate (p<0.05), 11deoxycortisol (p<0.0001), cortisol (p<0.05) and testosterone (p<0.01) significantly increased in female ACC patients when compared to male counterparts. Conclusion: Significant differences in plasma steroids were observed in ACC vs ACA patients, with more steroids altered in female patients. Serum steroid profiles, particularly steroid sulfates, might serve as an adjunct, easy to obtain diagnostic tool to differentiate ACA and ACC. Presentation: Friday, June 16, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10554608/ http://dx.doi.org/10.1210/jendso/bvad114.187 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Adrenal (Excluding Mineralocorticoids)
van Rooyen, Desmaré
Scheske, Rachel
Lerario, Antonio Marcondes
Rainey, William E
Auchus, Richard Joseph
Hammer, Gary D
Else, Tobias
FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA)
title FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA)
title_full FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA)
title_fullStr FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA)
title_full_unstemmed FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA)
title_short FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA)
title_sort fri192 serum steroid biomarkers for the differential diagnosis of adrenocortical carcinoma (acc) and adrenocortical adenoma (aca)
topic Adrenal (Excluding Mineralocorticoids)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554608/
http://dx.doi.org/10.1210/jendso/bvad114.187
work_keys_str_mv AT vanrooyendesmare fri192serumsteroidbiomarkersforthedifferentialdiagnosisofadrenocorticalcarcinomaaccandadrenocorticaladenomaaca
AT scheskerachel fri192serumsteroidbiomarkersforthedifferentialdiagnosisofadrenocorticalcarcinomaaccandadrenocorticaladenomaaca
AT lerarioantoniomarcondes fri192serumsteroidbiomarkersforthedifferentialdiagnosisofadrenocorticalcarcinomaaccandadrenocorticaladenomaaca
AT raineywilliame fri192serumsteroidbiomarkersforthedifferentialdiagnosisofadrenocorticalcarcinomaaccandadrenocorticaladenomaaca
AT auchusrichardjoseph fri192serumsteroidbiomarkersforthedifferentialdiagnosisofadrenocorticalcarcinomaaccandadrenocorticaladenomaaca
AT hammergaryd fri192serumsteroidbiomarkersforthedifferentialdiagnosisofadrenocorticalcarcinomaaccandadrenocorticaladenomaaca
AT elsetobias fri192serumsteroidbiomarkersforthedifferentialdiagnosisofadrenocorticalcarcinomaaccandadrenocorticaladenomaaca